

CLAIM LISTING

Claims 1-20. (Canceled)

Claim 21. (Currently amended) A method for treating a subject having an inflammatory disorder characterized by aberrant GM4,6D polypeptide activity or aberrant GM4,6D nucleic acid expression comprising administering to the subject a therapeutically effective amount of a GM4,6D modulator, thereby treating said subject having an inflammatory disorder.

Claim 22. (Canceled)

Claim 23. (Currently amended) A method for modulating an inflammatory response in a subject comprising administering to the subject a therapeutically effective amount of a GM4,6D modulator, thereby modulating an inflammatory response in said subject.

Claims 24-25. (Canceled)

Claim 26. (Currently amended) The method of claim 21[~~or claim 23~~], wherein the disorder is [~~a disorder selected from the group consisting of:~~] chosen from arthritis, transplant rejection, asthma, sepsis, reperfusion injury, stroke, infection, and leukocyte adhesion deficiency II.

Claim 27. (Previously presented) The method of claim 21 or claim 23, wherein the GM4,6D modulator is capable of modulating GM4,6D polypeptide activity.

Claim 28. (Previously presented) The method of claim 27, wherein the GM4,6D modulator is an inhibitor of GM4,6D activity.

Claim 29. (Previously presented) The method of claim 27, wherein the GM4,6D modulator is an anti-GM4,6D antibody.

Claims 30-37. (Canceled)

Claim 38. (Previously presented) A method for treating a subject having an inflammatory disorder characterized by excessive GM4,6D activity or excessive GM4,6D nucleic acid expression, comprising administering a therapeutically effective amount of an inhibitor capable of inhibiting the GM4,6D activity, wherein GM4,6D comprises SEQ ID NO:2 or SEQ ID NO:3.

Claim 39. (Currently amended) The method of claim 38, wherein the inflammatory disorder is ~~[a disorder selected from the group consisting of]~~ chosen from arthritis, transplant rejection, asthma, sepsis, reperfusion injury, stroke~~[,]~~ and infection~~[, and leukocyte adhesion deficiency II]~~.

Claim 40. (Currently amended) ~~[The method of either of claims 38 or 39]~~ A method for treating a subject having an inflammatory disorder, wherein the inflammatory disorder is characterized by excessive GM4,6D activity or excessive GM4,6D nucleic acid expression, [GM4,6D inhibitor is] comprising administering a therapeutically effective amount of an antibody capable of binding to a polypeptide comprising the amino acid sequence of either SEQ ID NO:2 or SEQ ID NO: 3.

Claim 41. (Previously presented) The method of claim 40, wherein the antibody is a monoclonal antibody.

Claim 42. (Previously presented) The method of claim 40, wherein the antibody is a polyclonal antibody.

Claim 43. (New) The method of claim 40, wherein the antibody is capable of binding to a polypeptide comprising the amino acid sequence of SEQ ID NO: 3.

Claim 44. (New) A method for treating a subject having an inflammatory disorder characterized by excessive GM4,6D activity or excessive GM4,6D nucleic acid expression and chosen from arthritis, transplant rejection, asthma, sepsis, reperfusion injury, stroke and infection, comprising administering a therapeutically effective amount of an antibody capable of binding to a polypeptide comprising the amino acid sequence of either SEQ ID NO:2 or SEQ ID NO: 3.

Claim 45. (New) The method of claim 44, wherein the antibody is a monoclonal antibody.

Claim 46. (New) The method of claim 44, wherein the antibody is a polyclonal antibody.

Claim 47. (New) The method of claim 44, wherein the inflammatory disorder is arthritis.

Claim 48. (New) The method of claim 44, wherein the inflammatory disorder is transplant rejection.

Claim 49. (New) The method of claim 44, wherein the inflammatory disorder is asthma.

Claim 50. (New) The method of claim 44, wherein the inflammatory disorder is stroke.

Claim 51. (New) The method of claim 44, wherein the inflammatory disorder is infection.

Claim 52. (New) A method of treating a subject having an inflammatory disorder characterized by excessive GM4,6D polypeptide activity comprising administering to the subject a compound, wherein said compound modulates GM4,6D polypeptide activity when combined with a substrate and a GM4,6D polypeptide chosen from:

(1) a polypeptide encoded by the nucleotide sequence of SEQ ID NO: 1;

(2) a polypeptide of SEQ ID NO: 2;

(3) a polypeptide of SEQ ID NO: 3;

(4) and a fragment of the polypeptide of SEQ ID NO:2 or SEQ ID NO: 3, which has GM4,6D activity.

Claim 53. (New) The method of claim 52, wherein the compound is an antibody that binds the GM4,6D polypeptide.

Claim 54. (New) The method of claim 52, wherein the antibody is a monoclonal antibody.

Claim 55. (New) The method of claim 52, wherein the antibody is a polyclonal antibody.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com